🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

New drugs @ASCO2025 Gustave Roussy

🔬Cancer of Unknown Primary NEJM ✅Excellent review with diagnostic/management algorithm 👉nejm.org/doi/full/10.10… OncoAlert Gil Morgan, MD #cancer #oncology #MedX #ASCO25

#ASCO2025 🚨 BREAKWATER OS data lands—and it must redefine 1L standard of care in BRAF V600E-mutant mCRC. EC + mFOLFOX6 vs SOC (chemo ± bevacizumab): 📊 PFS: 12.8 vs 7.1 mo (HR 0.53, p < 0.0001) 🧬 OS: 30.3 vs 15.1 mo (HR 0.49, p < 0.0001) ✅ Dual primary endpoints met 🛡️

📢1L Encorafenib, Cetuximab, and mFOLFOX6 in BRAF-Mut mCRC BREAKWATER NEJM #ASCO25 ✅EC+mFOLFOX6 vs SoC mOS: 30.3 vs 15.1 months HR: 0.49 (0.38 to 0.63) P<0.001 😮 👉nejm.org/doi/full/10.10… OncoAlert Medical.watch Dr Joseph McCollom DO #cancer #oncology #MedX #CRC

#ASCO25 1️⃣st relevant study 📚from a surgical🔪multi-disciplinary standpoint. CAIRO-6 Cytoreductive Surgery (CRS)+HIPEC in patients with PERITONEAL metastases ➕/➖ Systemic peri-operative My🔑take is 45-54 months OS 👀. Highest to date in peritoneal Mets. OncoAlert #CRCSM

#ASCO25 started with very interesting data on #NET Jaume Capdevila from Vall d’Hebron Institute of Oncology (VHIO) on #obrixtamig in #epNEC BITE-Phase I Manageable safety (CRS) Higher ORR and longer DOR if highDLL3 DAREON-5 trial ongoing in highDLL3 Combos with chemo for lowDLL3? Grupo GETNE ASCO NET- ESPAÑA

📣CASSANDRA #ASCO25 Neoadj Gem + nabP + Cis + Capecitabine vs FOLFIRINOX in res/borderline res PDAC ✅3y EFS 30% vs 14%, HR: 0.76, p=0.005 ❗️G3/4 Neutropenia 44% vs 30% ✅G3/4 Infection: 6% vs 9% OncoAlert ASCO #cancer #oncology #MedX #pancreatic

#ASCO2025 #TTDUpdates Trastuzumab Deruxtecan or Ramucirumab plus Paclitaxel in Gastric Cancer nejm.org/doi/full/10.10… 👉OS 14.7 vs 11.4 mo HR 0.70 | p=0.004 👉PFS: 6.7 vs 5.6 mo 👉ORR: 44.3% vs 29.1% ILD/pneumonitis in 13.9% HER2 "rebiopsy" post-trastuzumab is mandatory

🧠⚡ PANOVA-3: TTFields in LA-PAC 🧪 TTFields + Gem/NabPac vs chemo alone 👥 n=571 | 📍 Phase 3 | 🎯 OS primary ✅ OS: 16.2 vs 14.2 mo 📉 HR 0.82 [0.68–0.99], p=0.039 🩻 1-yr OS: 68% vs 60% ❌ No PFS or local PFS benefit 📍 Distant PFS only in post-hoc 😣 81% device-related AEs

Pre-operative mFOLFIRINOX or PAXG regimen for stage I-III #PDAC #ASCO25 🔎Phs-III 👉mEFS 16.2 vs 10 mo 👉mOS 37 vs 26 mo 🧐 OS benefit, but intensive treatment ESMO - Eur. Oncology

#ASCO25 Neoadjuvant or adjuvant in dMMR colon cancer? Looks like we’ll be discussing this at length today. Let’s start with this comparison👇

The most practice changing trial from #ASCO25 is now live on NEJM .If this was a drug, this would be approved today. Globally relevant and low-cost intervention that is not only delaying relapse but actually improving survival. Perfect case example of a #cancergroundshot trial.

🔥Plenary Discussion of LBA5🔥 📷 #ASCO2025 👏Great discussion by Sam Klempner 👉D-FLOT reached it's primary endpoint and will change clinical practice 👉More to come: from MATTERHORN to EVEREST ESMO - Eur. Oncology

So you've heard the practice changing exercise CHALLENGE trial! But what did that groundbreaking exercise program actually look like day-to-day? Let's explore the "Structured Exercise Program" based on info from their paper supplement on NEJM #ASCO2025 #ASCO25 1/10

TEDOPAM - maintenance randomised phase 2 vaccine trial #PDAC Induction mFFX- Folfiri vs Folfiri+ OSE2101 (TAAs) ➡️106 pts ➡️met primary endpoint of 12mth OS>50%; ➡️But control arm mOS 17 vs vaccine arm 15mths ➡️highlights benefit maintenance approaches ASCO OncoAlert #ASCO25

🔥NeoPancOne🇨🇦 ➡️mFFX in resectable PDAC ➡️exploring GATA6&subtypes ➡️mEFS &OS 16.3 &34.2mths ➡️1yr EFS 90% in GATA6 hi vs 50% lo ➡️1yr OS classical 95% vs.57% basal-like ⭐️Time to subtype upfront in all PDAC recognising plasticity OncoAlert #ASCO25 Ontario Institute for Cancer Research (OICR) Princess Margaret Cancer Centre

10-year follow up for pembro in MSI-H/dMMR advanced solid tumors 🔎KEYNOTE 16 👉10-yrs OS rate: 46% 👉Rare progression after 2 years 👉We need biomarker to identify (non-) responders 🧐 Great to see 10yr survival data for systemic therapies ESMO - Eur. Oncology

#ASCO25 This is the 1st time I started hearing the word “CURE” in patients with metastatic stage-IV cancers: ✅MSI-High cancers 🟰 #Immunotherapy 10 year survival 47% Progression beyond 2 years is exceedingly rare; a gift that keeps giving. OncoAlert ✔️Check 💯% Reflexive🔬

Zanidatamab plus chemotherapy as first-line treatment for patients with HER2-positive advanced gastro-oesophageal adenocarcinoma: primary results of a multicentre, single-arm, phase 2 study - The Lancet Oncology ⁦OncoAlert⁩ #ASCO25 thelancet.com/journals/lanon…

BTC care is evolving fast—catch up on the latest insights from PeerView, Arndt Vogel, James J. Harding, MD & Teresa Macarulla in this on-demand #ASCO25 symposium. 📽️ Watch the recording: peerview.com/2025Biliary